Neurogene Inc.

NGNESEC EDGAR

Pharmaceutical PreparationsCIK: 1404644

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	—	—	—	—
Research and Development Expense	$44.4M	$47.5M	$39.2M	—	—
Operating Expenses	$55.6M	$56.5M	$60.7M	—	—
Operating Income (Loss)	-$55.6M	-$56.5M	-$60.7M	-$33.7M	-$71.0M
Interest Expense	—	$2.0K	—	—	—
Nonoperating Income (Expense)	—	—	-$13.0K	$451.0K	$1.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$36.3M	-$55.2M	-$60.7M	-$33.3M	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$222.6M	$109.3M	$163.3M	$210.5M	$147.0M
Assets, Current	$200.3M	$84.7M	$144.0M	$194.5M	$143.6M
Cash and Cash Equivalents, at Carrying Value	$148.2M	$82.0M	$142.5M	$192.6M	$143.1M
Liabilities	$36.5M	$10.6M	$20.4M	$19.3M	$5.3M
Liabilities, Current	$23.0M	$6.7M	$8.6M	$7.9M	$4.7M
Accounts Payable, Current	$2.6M	$625.0K	—	—	—
Stockholders' Equity Attributable to Parent	-$145.7M	-$91.9M	$191.2M	$141.7M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$51.4M	-$52.8M	-$47.6M	-$24.6M	-$15.4M
Net Cash Provided by (Used in) Investing Activities	$25.6M	-$2.2M	-$3.3M	-$2.2M	-$688.0K
Net Cash Provided by (Used in) Financing Activities	$92.5M	$66.5M	$732.0K	$77.1M	$82.2M
Payments to Acquire Property, Plant, and Equipment	$321.0K	$2.2M	$3.3M	$2.2M	$879.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)